Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation (NASDAQ: IRMD) is focused on MRI-compatible medical devices, and its news flow reflects that specialization. The company regularly issues press releases describing its financial results, product clearances, board changes, and capital allocation decisions. Investors and observers following IRMD news can see how its non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems perform in the marketplace and how management communicates about growth and operations.
Recent news has highlighted record quarterly revenue over multiple consecutive quarters, along with updates on gross margins, domestic and international sales mix, and cash flow from operations. The company also reports on its use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow, explaining how these metrics relate to its GAAP results. Dividend announcements, including regular quarterly cash dividends and a special cash dividend, are another recurring theme in iRadimed’s news releases.
Product and regulatory developments are also covered in detail. For example, iRadimed announced FDA 510(k) clearance for its MRidium 3870 IV Infusion Pump System, described as a next-generation MRI-compatible infusion pump with a non-magnetic ultrasonic motor, non-interfering RF emissions, and advanced safety and user interface features. News items also describe the capabilities of the 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss and is designed to travel with patients between critical care units and MRI suites.
Governance and recognition-related news includes disclosures about changes in the Board of Directors and iRadimed’s inclusion in TIME’s list of America’s Growth Leaders for 2026. Conference participation announcements and earnings call schedules provide additional context for those who want to follow company presentations and management commentary. For anyone tracking IRMD, this news feed offers a consolidated view of its financial performance, product milestones, governance updates, and other corporate developments.
IRADIMED CORPORATION (NASDAQ: IRMD) reported preliminary fourth-quarter 2022 revenue of $14.9 million, marking a 25% increase from the previous year and surpassing guidance of $14.1 million to $14.8 million. This achievement reflects six consecutive quarters of revenue growth, with full-year revenue up 27.5% year-over-year. For 2023, the company projects revenue between $61 million and $63 million and diluted earnings per share of $1.10 to $1.20. The first quarter guidance anticipates revenue of $14.6 million to $14.9 million and diluted earnings per share of $0.23 to $0.25. These results signify strong demand for their MRI-compatible medical devices.
IRADIMED CORPORATION (NASDAQ: IRMD) reported strong financial results for Q3 2022, with revenue reaching $13.4 million, a 23% increase year-over-year, and operating income of $4.1 million, up 32%. GAAP diluted EPS increased 35% to $0.27. For the first nine months, total revenue was $38.4 million, compared to $30.0 million in 2021. The company also announced plans to purchase 27 acres for future expansion in Orlando, Florida and anticipates consistent growth with stronger bookings.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2022 third quarter financial results on November 3, 2022, before market opening. A conference call to discuss these results is scheduled for the same day at 11:00 a.m. Eastern Time. Interested participants can register for the call online.
IRADIMED specializes in innovative MRI-compatible medical devices, including its patented MRidium IV infusion pump and the IRADIMED 3880 vital signs monitoring system, both designed to optimize patient safety and care during MRI procedures.
IRADIMED CORPORATION announced preliminary financial results for Q3 2022, reporting approximately $13.4 million in revenue, a 23% increase from the prior year, surpassing guidance of $13.1 million - $13.3 million. This marks the company's highest revenue quarter and a continuation of a four-quarter trend of record revenues. However, the company voluntarily withdrew its 510(k) application for the MR IV pump due to the FDA's request for additional information, which they aim to resolve for a future resubmission.
IRADIMED CORPORATION (NASDAQ: IRMD) announced the appointment of Hilda Scharen-Guivel to its Board of Directors, effective October 4, 2022. With her extensive experience in regulatory oversight within the medical device industry, including her recent role at the FDA, her expertise is expected to be pivotal as the company develops new products. Following her appointment, the Board consists of five directors, three of whom are independent. IRADIMED specializes in MRI-compatible medical devices, and the addition of Scharen-Guivel may enhance the company’s growth trajectory.
IRADIMED CORPORATION (NASDAQ: IRMD) reported a record second quarter 2022 revenue of $12.7 million, marking a significant increase from $9.8 million in Q2 2021. Diluted GAAP EPS was $0.26, up from $0.12 year-over-year. For the six months ended June 30, revenue reached $25.0 million compared to $19.0 million in the same period in 2021. The company anticipates third-quarter guidance of $13.1 million to $13.3 million in revenue and full-year guidance of $52.5 million to $53.2 million.
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its 2022 Q2 financial results on July 29, 2022, before the market opens. Management will hold a conference call at 11:00 a.m. ET the same day to discuss the results and answer questions. The call will be available online, and a recording will be accessible later on the company's website. IRADIMED is recognized for its innovative MRI-compatible medical devices, including the MRidium® IV infusion pump and 3880 vital signs monitoring system, designed to safely deliver anesthesia and monitor patients during MRI procedures.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its 2022 second quarter financial results on July 29, 2022, before market opening. A conference call will be held on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions from investors. Interested parties can register for the call via the provided link. The company specializes in MRI-compatible medical devices, notably its MRidium® IV infusion pump and the 3880 vital signs monitoring system, designed to enhance patient safety during MRI procedures. More details can be found on their official website.
Perimeter Medical Imaging AI has appointed Chris Scott as the new Chief Financial Officer, effective immediately. Scott brings extensive experience in the medtech sector, having previously served as CFO at iRadimed Corporation (NASDAQ: IRMD) and successfully led them through an IPO, increasing their market cap from $10 million to $600 million. The company is well-positioned with a strong balance sheet and is focused on further developing its S-Series OCT and next-gen AI technology.
IRADIMED CORPORATION (NASDAQ:IRMD) has appointed John (Jack) Glenn as its new Chief Financial Officer, effective on or before June 20, 2022. With over 30 years of experience in corporate finance, Glenn's expertise includes roles at Esko Bionics and Sonendo, as well as a strong background in the medical device sector. The company, recognized for its innovative MRI-compatible medical devices, aims to leverage Glenn's strategic financial management to support its ongoing growth trajectory, as stated by CEO Roger Susi.